Want to see DE:GXI full AI Analyst Report?
Top Page
Gerresheimer
(XETRA:GXI)
Select Model
Select Model
Rating:54Neutral
Price Target:
€33.00
▲(23.97% Upside)
Action:Reiterated
Date:10/20/26
The score is held back primarily by weakened financial performance, driven by the swing to losses, higher leverage, and significantly negative free cash flow despite positive operating cash flow. Technicals are a clear positive with an uptrend and strong momentum, though overbought signals add near-term risk. Valuation is mixed: a high dividend yield supports the stock, but the negative P/E reflects loss-making results and reduces valuation reliability.
Positive Factors
Steady Revenue Growth
Revenue growth across several years indicates expanding demand for Gerresheimer’s pharmaceutical packaging and delivery products. Continued top-line expansion provides a durable base for operating leverage and supports investment in specialized products, customer programs, and future capacity.
Negative Factors
Swing to Net Loss
The shift from consistent operating profitability in 2020–2024 to substantial EBIT and net losses in 2025 is a material deterioration in earnings quality. If not reversed, weaker profitability could reduce reinvestment capacity and undermine returns from the company’s growing revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Revenue growth across several years indicates expanding demand for Gerresheimer’s pharmaceutical packaging and delivery products. Continued top-line expansion provides a durable base for operating leverage and supports investment in specialized products, customer programs, and future capacity.
Read all positive factors
Gerresheimer (GXI) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.12B
Dividend Yield0.12%
Average Volume (3M)142.72K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth8.90%
EPS Growth-609.05%
CountryDE
Employees13,301
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-11.61
Shares Outstanding34,540,000
10 Day Avg. Volume208,462
30 Day Avg. Volume142,721
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.40
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.55Price Target Upside7.25% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)1.84
Revenue Forecast (FY)€2.35B
Gerresheimer Business Overview & Revenue Model
Company Description
Gerresheimer AG, founded in 1864 and based in Düsseldorf, Germany, is a global supplier specializing in the production and sale of packaging solutions and sophisticated drug delivery systems. The company operates through three distinct divisions. ...
How the Company Makes Money
Gerresheimer makes money primarily by manufacturing and selling pharma- and healthcare-focused packaging and drug delivery products to customers such as pharmaceutical and biotechnology companies and other healthcare product manufacturers. Key rev...
Gerresheimer Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
48
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | May 2026 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.28B | 2.32B | 2.04B | 1.99B | 1.82B | 1.50B |
| Gross Profit | 347.76M | 425.25M | 607.76M | 597.31M | 546.81M | 442.23M |
| EBITDA | 238.06M | 75.58M | 405.97M | 403.89M | 340.32M | 293.84M |
| Net Income | -400.62M | -320.32M | 109.72M | 116.13M | 96.12M | 83.79M |
Balance Sheet | ||||||
| Total Assets | 4.35B | 4.49B | 3.81B | 3.43B | 3.35B | 2.88B |
| Cash, Cash Equivalents and Short-Term Investments | 167.61M | 176.21M | 213.06M | 122.34M | 124.83M | 133.78M |
| Total Debt | 2.21B | 1.60B | 1.28B | 1.04B | 1.22B | 1.13B |
| Total Liabilities | 3.37B | 3.39B | 2.27B | 1.96B | 2.08B | 1.88B |
| Stockholders Equity | 956.47M | 1.08B | 1.51B | 1.45B | 1.24B | 981.32M |
Cash Flow | ||||||
| Free Cash Flow | 369.47M | -98.80M | -129.51M | -33.70M | -16.13M | 8.45M |
| Operating Cash Flow | 261.60M | 209.53M | 240.33M | 294.34M | 221.94M | 212.08M |
| Investing Cash Flow | -240.87M | -661.77M | -345.59M | -307.43M | -256.18M | -197.04M |
| Financing Cash Flow | 40.30M | 452.97M | 168.27M | 40.35M | 44.24M | 8.03M |
Gerresheimer Technical Analysis
Positive
26.62
Price Trends
28.55
Positive
27.92
Positive
25.21
Positive
Market Momentum
1.26
Negative
62.67
Neutral
71.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GXI, the sentiment is Positive. The current price of 26.62 is below the 20-day moving average (MA) of 30.18, below the 50-day MA of 28.55, and above the 200-day MA of 25.21, indicating a bullish trend. The MACD of 1.26 indicates Negative momentum. The RSI at 62.67 is Neutral, neither overbought nor oversold. The STOCH value of 71.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:GXI.
Gerresheimer Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €832.23M | 16.63 | 19.49% | 1.65% | 4.42% | 35.68% | |
66 Neutral | €1.68B | 11.44 | 10.62% | 2.17% | 6.37% | 71.55% | |
62 Neutral | €18.05B | 92.56 | 6.92% | 0.32% | 4.19% | 63.32% | |
60 Neutral | €278.37M | -572.50 | -0.17% | 2.62% | ― | ― | |
59 Neutral | €1.60B | 23.60 | 12.29% | 4.51% | 0.35% | 116.73% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €1.12B | -2.78 | -32.84% | 0.12% | 8.90% | -609.05% |
* General Sector Average
DE:GXI
Gerresheimer
32.30
3.46
12.00%
DE:DRW3
Draegerwerk AG & Co. KGaA
104.60
35.00
50.30%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
13.30
-3.31
-19.93%
DE:PFV
Pfeiffer Vacuum Technology
162.40
13.66
9.18%
DE:SRT
Sartorius
230.00
38.63
20.19%
DE:SBS
STRATEC Biomedical
22.90
-1.17
-4.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.